Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-12-05
2009-02-24
Blanchard, David J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S388220, C530S388730, C530S388800, C424S133100, C424S141100, C424S144100, C424S155100, C435S069600, C435S070210
Reexamination Certificate
active
07495081
ABSTRACT:
Framework (FR)-patching is a novel approach to modify immunoglobulin for reducing potential immunogenicity without significant alterations in specificity and affinity. Unlike previous described methods of humanization, which graft CDRs from a donor onto the frameworks of a single acceptor immunoglobulin, we patch segments of framework (FR1, FR2, FR3, and FR4), or FRs, to replace the corresponding FRs of the parent immunoglobulin. Free assortment of these FRs from different immunoglobulins and from different species can be mixed and matched into forming the final immunoglobulin chain. A set of criteria in the choice of these FRs to minimize or eliminate the need to reintroduce framework amino acids from the parent immunoglobulin for patching is described. The approach gives greater flexibility in the choice of framework sequences, minimizes the need to include parent framework amino acids, and, most importantly, reduces the chances of creating new T- and B-cell epitopes in the resultant immunoglobulin.
REFERENCES:
patent: 4704362 (1987-11-01), Itakura et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5789554 (1998-08-01), Leung et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 5908925 (1999-06-01), Cohen
patent: 6187287 (2001-02-01), Leung et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 4225853 (1994-02-01), None
patent: 0239400 (1987-09-01), None
patent: WO 9702671 (1987-05-01), None
patent: WO 9734632 (1997-09-01), None
patent: WO 9841641 (1998-09-01), None
patent: WO 9955369 (1999-11-01), None
Johnson, Syd et al., Journal of Infectious Diseases, 1997; 176:1215-1224.
Adair, Fiona et al., BioPharm, Oct. 2000, pp. 42-46.
Amit, et al., Science, 1986; 233:747-753.
Benhar, et al., PNAS USA, 1994; 91(25) 12051-12055.
Bird, et al., Science, 1988; 242: 423-426.
Bruccoleri, et al., Nature, 1988; 335: 564-568.
Chatterjee, et al., Cancer Immunol. Immunother., 1994; 38: 75-82.
Chothia, et al., Nature, 1989; 342:877.
Chothia, et al., Science, 1986; 233: 755-758.
Chothia and Lesk, J. Mol. Biol., 1990; 215:175.
Coiffier, et al., Blood, 1998; 92: 1927-1932.
Co, Man Sung et al., PNAS USA, 1991; 88:2869-2973.
Daugherty, et al., Nucl. Acid Res., 1991; 19: 24712476.
Davis et al., J. Clin. Oncol., 1999; 17: 1851-1857.
Gillam and Smith, Gene, 1979; 8: 81-97.
Gura, Science, 1997; 278: 1041-1042.
Hamilton, et al., Journal of Infectious Diseases, 1997: 176:59-68.
Hunkapiller and Hood, Nature, 1986; 323:15-16.
Huston et al, PNAS USA, 1988; 85: 5879-5833.
Jones et al., Nature, 1986; 321: 522-525.
Kabat et al., Journal of Immunology, 1991; 147 (5): 1709-1719.
Leung et al., Mol. Immunol., 1995; 32: 1413-1427.
Levy et al., Biochemistry, 1989; 28:7168-7175.
Lewis et al., Immunology, 1993; 7: 110-118.
Li et al., Cell. Immunol., 1989; 118:85.
Mansfield et al., Blood, 1997; 90:2020-2026.
McLaughlin et al., J. Clin. Oncol., 1998; 16: 2825-2833.
Ohtomo et al., Mol. Immunol., 1995; 32: 407-416.
Padlan et al., Mol. Immunol., 1994: 31(3): 169-217.
Paul et al.,Fundamental Immunology, Raven Press, New York, 1993: Chapter 8, p. 242.
Riechmann et al., Nature, 1988; 332: 323-327.
Roberts et al., Nature, 1987: 328:731-734.
Roguska et al., Protein Engineering, 1996: 9: 895-904.
Rosok et al., Journal of Biological Chemistry, 1996; 271(37): 22611-22618.
Rudikoff et al., PNAS, 1982; 79: 1979.
Rudikoff et al., PNAS USA, 1979; 79: 1979.
Sanger et al., PNAS, 1977; 74: 5463-5467.
Shan et al., Journal of Immunology, 1999'; 162: 6589-6595.
Shaw et al., J. Immunol., 1987; 138:4534-4538.
Shearman et al., Journal of Immunology, 1991; 147 (12): 4366-4373.
Singer et al., J. Immunol., 1993; 150: 2844-2857.
Tramamoto et al., J. Mol. Biol., 1990; 215: 175.
Verhoyen et al., Science, 1988; 85: 5879-5833.
Wu et al., Molecular Immunology, 1992; 29 (9): 1141-1146.
Wu et al., Applied Biochem and Biotech, 1994: 47: 107-118.
Zhengxing, et al., Clinical Cancer Research, 1999; vol. 5 (Suppl.):3095s-3100s.
International Search Report (Sep. 19, 2002), Written Opinion (Jan. 16, 2003), and Preliminary Examination Report (Dec. 19, 2003) for International Application No. PCT/US02/18512, filed Jun. 10, 2002, to Shawn Shui-on Leung.
Supplemental European Search Report from the European Patent Office (Jan. 30, 2007) for European Patent Application No. EP 02734771, filed Jan. 26, 2004, to Shawn Shiu-on Leung.
Complaint for Declaratory Judgment and Permanent Injunction (Including Exhibits A-G), Motion for Special Process Servers, Order Appointing Special Process Servers from Civil Action No. 2471-N, Oct. 12, 2006.
Supplemental Information Pursuant to Rule 3(a) of the Rules of the Court of Chancery, Oct. 12, 2006.
Blanchard David J.
Skytech Technology Limited
Smith Chalin A.
Smith Patent Consulting
LandOfFree
Framework patched anti-CD20 antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Framework patched anti-CD20 antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Framework patched anti-CD20 antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4063613